INVENTORY TURNS AND PROFITABILITY TRENDS CONTINUE TO SLIP FOR WHSLRS.
Executive Summary
Average inventory turnover by drug wholesalers declined for the third straight year in 1986, according to the most recent Operating Survey released by the National Wholesale Druggists Association. From a 7.31 turnover rate in 1983, the median drug wholesaler has slipped to 6.39 inventory turns. Similarly, wholesalers continued to experience the recent trend of narrowing profit margins, NWDA reported. "The industry's overall profitability is now approaching that of most other wholesale commodity lines," the survey states. "Another year of decline similar to that seen in 1986, and it will probably be below the returns available from other wholesale lines." The squeeze of profit margins favors high-volume operations, the report notes. The "strong relationship between sales and profitability is highlighted" by the fact that "most houses under $20 mil. in sales lost money in 1986" and that "there is not too much difference in the profitability performance of the over-$20 mil. houses," NWDA said. "It appears that a number of small, under-$20 mil. houses are losing money and are candidates for closure," the report states. "Their particularly weak performance has been pulling down overall industry profitability."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth